Earnings release
Page 1
Exhibit 99.1 CareDx Announces Third Quarter 2026 Financial Results Third Quarter Revenue Growth of 39% to $139 Million Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million BRISBANE, Calif. — (BUSINESS WIRE) — CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights • Revenue of $139 million, an increase of 39% year-over-year • Testing Services revenue of $119 million, an increase of 65% year-over-year • Testing Services volume of approximately 75,900, an increase of 51% year-over-year, including contributions following our acquisition of NavDx • Patient and Digital Solutions revenue of $20 million, an increase of 31% year-over-year • GAAP net income of $19 million, compared with GAAP net income of $2 million for the third quarter of 2025 • Closed the acquisition of Naveris, Inc. on July 1, 2026 for $160 million in cash consideration and up to $100 million in contingent consideration • Adjusted EBITDA of $30 million, compared with $15 million for the third quarter of 2025 • Cash flow from operations of $13 million Recent Business Highlights • Advanced AlloHeme toward a planned first-quarter 2027 commercial launch and HistoMap Kidney toward broader commercial availability in 2027, with both programs targeting CLIA readiness before year-end • Published new HistoMap data in Transplantation demonstrating its potential to identify clinically meaningful risk beyond conventional pathology • Broadened the clinical evidence for NavDx across multiple contexts of use, including a newly published eight-center study of 332 patients evaluating molecular results during the first three months after treatment and two independent Phase II studies exploring radiation de-escalation after surgery and during definitive treatment • Presented new KOAR registry data demonstrating the potential for AlloSure Kidney to identify patients at greater risk of graft loss or declining kidney function when biopsy findings are difficult to interpret • Advanced commercial and workflow execution across the portfolio, including continued Epic Aura adoption, more than 5,000 transplant patients registered for the new CareDx patient portal, and the migration of NavDx to the CareDx billing platform “We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy,” said John Hanna, President and Chief Executive Officer of CareDx. “We see significant clinical interest in how molecular information can inform more decisions across a patient’s care journey, while continuing to make our solutions easier for providers to adopt and patients to access. We believe these dynamics create meaningful opportunities for continued profitable growth.”
Page 2
Third Quarter 2026 Financial Results Total revenue was $139 million, compared with $100 million in the third quarter of 2025, an increase of 39% year-over-year, driven primarily by growth in Testing Services and Patient and Digital Solutions revenue, including the addition of Specialty Oncology revenue following our acquisition of NavDx. Testing Services revenue was $119 million, compared with $72 million in the third quarter of 2025, an increase of 65% year- over-year, including $12 million in Specialty Oncology revenue. Testing Services revenue includes $15 million in prior period revenue, compared with $6 million in the third quarter of 2025. Testing Services volume was approximately 75,900, an increase of 51% year-over-year, including contributions from Specialty Oncology. Excluding revenue recognized for tests performed in prior periods, Testing Services revenue increased approximately 58% year-over-year. Patient and Digital Solutions revenue was $20 million, compared with $15 million in the third quarter of 2025, an increase of 31% year-over-year, driven primarily by continued growth in CareDx Pharmacy services. As a reminder, the Company completed the divestiture of its Lab Products business on June 30, 2026. Accordingly, the Company’s third quarter 2026 results do not include Lab Products revenue. GAAP net income was $19 million, compared with GAAP net income of $2 million in the third quarter of 2025. Basic and diluted GAAP net income per share were $0.37 and $0.35, respectively, compared with basic and diluted GAAP net income per share of $0.03 in the third quarter of 2025. GAAP net income margin was approximately 14%, compared with approximately 2% in the third quarter of 2025. Adjusted EBITDA was $30 million, compared with $15 million in the third quarter of 2025, driven by revenue growth, higher gross profit and disciplined operating expense management. Adjusted EBITDA margin was approximately 22%, compared with approximately 15% in the third quarter of 2025. 2026 Guidance For the full year 2026, CareDx now expects revenue to be in the range of $520 million to $530 million, compared with its previously disclosed range of $490 million to $500 million. The Company now expects full-year 2026 Adjusted EBITDA to be in the range of $90 million to $100 million, compared with its previously disclosed range of $66 million to $78 million. About CareDx CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, please visit www.caredx.com. Forward-Looking Statements This press release includes forward-looking statements, including expectations regarding the achievement of CareDx’s financial and operational goals and its expectations and prospects for 2026 and beyond. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx’s control, that could cause the actual results to differ materially from those projected, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or
Page 3
implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. Use of Non-GAAP Financial Measures CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and also on a non-GAAP basis, including non-GAAP cost of testing services, non-GAAP cost of product, non-GAAP cost of patient and digital solutions, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other income, net, non-GAAP income tax expense, non-GAAP gross profit, non-GAAP gross margin (%), non-GAAP operating expenses, non-GAAP net income, non-GAAP basic and diluted net income per share, adjusted EBITDA and adjusted EBITDA margin. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. We define non-GAAP net income and per share results as the GAAP net income (loss) and per share results excluding the impacts of stock-based compensation expense; acquisition-related amortization of purchased intangible assets and related tax effects; changes in estimated fair value of contingent consideration; litigation settlement expense; business development and portfolio optimization expense; gain on sale of lab product business; and certain other charges presented in the reconciliation in this release. We define adjusted EBITDA as non-GAAP net income before interest income, income tax expense, depreciation expense and other (income) expense, net. We define non-GAAP gross profit and non-GAAP gross margin as GAAP gross profit and GAAP gross margin excluding the impacts of stock-based compensation expense, and acquisition- related amortization of purchased intangible assets included in cost of sales. Non-GAAP gross margin is calculated as non- GAAP gross profit divided by total revenue. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by total revenue. Corporate free cash flow is defined as Cash from Operations less Capital Expenditures. We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods where certain items may vary independent of business performance. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx’s operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables. A reconciliation of the forecasted range for adjusted EBITDA for 2026 is not included in this release due to the number of variables in the projected range and because we are currently unable to quantify accurately certain amounts that would be required to be included in the U.S. GAAP measure or the individual adjustments for such reconciliation. CareDx, Inc. Media Relations Natasha Moshirian Wagner nwagner@CareDx.com Investor Relations Nina Deka investor@CareDx.com
Page 4
CareDx, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) Three Months Ended September 30, 2026 2025 Revenue: Testing services revenue $ 119,191 $ 72,168 Product revenue — 12,478 Patient and digital solutions revenue 20,171 15,409 Total revenue 139,362 100,055 Operating expenses: Cost of testing services 24,683 14,705 Cost of product — 5,629 Cost of patient and digital solutions 15,604 10,320 Research and development 21,324 16,769 Sales and marketing 31,650 24,449 General and administrative 37,989 28,429 Total operating expenses 131,250 100,301 Income (loss) from operations 8,112 (246) Other income: Interest income, net 2,208 2,013 Other income (expense), net 372 (107) Total other income 2,580 1,906 Income before income taxes 10,692 1,660 Income tax benefit 8,600 15 Net income $ 19,292 $ 1,675 Net income per share: Basic $ 0.37 $ 0.03 Diluted $ 0.35 $ 0.03 Weighted-average shares used to compute net income (loss) per share: Basic 52,116,051 52,507,582 Diluted 54,984,989 53,736,790
Page 5
CareDx, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands) As of September 30, 2026 December 31, 2025 Assets Current assets: Cash and cash equivalents $ 250,480 $ 65,429 Marketable securities — 111,779 Accounts receivable 47,730 42,628 Inventory 9,144 26,705 Prepaid and other current assets 13,943 10,591 Total current assets 321,297 257,132 Property and equipment, net 27,011 32,971 Operating lease right-of-use assets 23,541 22,760 Marketable securities, non-current — 24,165 Intangible assets, net 139,781 31,960 Goodwill 121,709 40,336 Restricted cash 1,410 551 Other assets 6,708 3,353 Total assets $ 641,457 $ 413,228 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 10,808 $ 9,988 Accrued compensation 40,564 38,107 Accrued and other liabilities 87,603 41,754 Total current liabilities 138,975 89,849 Deferred tax liability 536 181 Contingent consideration, non-current 14,035 161 Operating lease liabilities, less current portion 20,316 19,679 Other liabilities 139 257 Total liabilities 174,001 110,127 Commitments and contingencies Stockholders’ equity: Common stock 52 50 Additional paid-in capital 953,558 927,457 Accumulated other comprehensive loss — (5,515) Accumulated deficit (486,154) (618,891) Total stockholders’ equity 467,456 303,101 Total liabilities and stockholders’ equity $ 641,457 $ 413,228
Page 6
CareDx, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (In thousands) Three Months Ended September 30, 2026 2025 Cost of testing services reconciliation: GAAP cost of testing services $ 24,683 $ 14,705 Stock-based compensation expense (213) (299) Restructuring costs — (120) Acquisition related-amortization of purchased intangibles (2,925) (348) Non-GAAP cost of testing services $ 21,545 $ 13,938 Cost of product reconciliation: GAAP cost of product $ — $ 5,629 Stock-based compensation expense — (51) Acquisition related-amortization of purchased intangibles — (447) Restructuring costs — (11) Non-GAAP cost of product $ — $ 5,120 Cost of patient and digital solutions reconciliation: GAAP cost of patient and digital solutions $ 15,604 $ 10,320 Stock-based compensation expense (96) (118) Acquisition related-amortization of purchased intangibles (152) (152) Restructuring costs — 8 Non-GAAP cost of patient and digital solutions $ 15,356 $ 10,058 Research and development expenses reconciliation: GAAP research and development expenses $ 21,324 $ 16,769 Stock-based compensation expense (1,197) (1,146) Restructuring costs — (174) Non-GAAP research and development expenses $ 20,127 $ 15,449 Sales and marketing expenses reconciliation: GAAP sales and marketing expenses $ 31,650 $ 24,449 Stock-based compensation expense (831) (1,782) Acquisition related-amortization of purchased intangibles (817) (655) Transformational initiative costs — (183) Restructuring costs — (233) Non-GAAP sales and marketing expenses $ 30,002 $ 21,596 General and administrative expenses reconciliation: GAAP general and administrative expenses $ 37,989 $ 28,429 Business development and portfolio optimization expense* (5,527) — Stock-based compensation expense (7,318) (5,022) Impairment of intangible asset — (2,258) Transformational initiative costs — (341) Non-GAAP general and administrative expenses $ 25,144 $ 20,808 Total other income reconciliation: GAAP other income $ 2,580 $ 1,906 Non-GAAP other income $ 2,580 $ 1,906 Income tax benefit (expense) reconciliation: GAAP income tax benefit $ 8,600 $ 15 Tax effect related to amortization of purchased intangibles — (111) Non-GAAP income tax benefit (expense) $ 8,600 $ (96) * Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.
Page 7
CareDx, Inc. GAAP and Non-GAAP Operating Expenses (Unaudited) (In thousands) Three Months Ended September 30, 2026 2025 GAAP operating expenses: Research and development $ 21,324 $ 16,769 Sales and marketing 31,650 24,449 General and administrative 37,989 28,429 Total GAAP operating expenses $ 90,963 $ 69,647 Non-GAAP operating expenses: Research and development $ 20,127 $ 15,449 Sales and marketing 30,002 21,596 General and administrative 25,144 20,808 Total Non-GAAP operating expenses $ 75,273 $ 57,853
Page 9
CareDx, Inc. Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin (Unaudited) (In thousands, except percentages) Three Months Ended September 30, 2026 June 30, 2026 September 30, 2025 GAAP total revenue $ 139,362 $ 131,948 $ 100,055 GAAP cost of sales 40,287 34,966 30,654 GAAP gross profit 99,075 96,982 69,401 GAAP gross margin % 71 % 74 % 69 % Stock-based compensation expense 309 321 468 Restructuring costs — — 123 Business development and portfolio optimization expense* — 311 — Acquisition related-amortization of purchased intangibles 3,077 355 947 Non-GAAP gross profit $ 102,461 $ 97,969 $ 70,939 Non-GAAP gross margin % 74 % 74 % 71 % * Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.
Page 10
CareDx, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (In thousands, except share and per share data) Three Months Ended September 30, 2026 2025 GAAP net income $ 19,292 $ 1,675 Stock-based compensation expense 9,655 8,418 Business development and portfolio optimization expense* 5,527 — Acquisition related-amortization of purchased intangibles 3,894 1,602 Tax effect related to amortization of purchased intangibles — (111) Impairment of intangible asset — 2,258 Transformational initiative costs — 524 Restructuring costs — 530 Non-GAAP net income $ 38,368 $ 14,896 GAAP basic net income per share $ 0.37 $ 0.03 GAAP diluted net income per share $ 0.35 $ 0.03 Non-GAAP basic net income per share $ 0.74 $ 0.28 Non-GAAP diluted net income per share $ 0.70 $ 0.28 Shares used in computing non-GAAP basic net income per share 52,116,051 52,507,582 Shares used in computing non-GAAP diluted net income per share 54,984,989 53,736,790 * Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.
Page 12
CareDx, Inc. Reconciliation of Non-GAAP to Adjusted EBITDA (Unaudited) (In thousands) Three Months Ended September 30, 2026 June 30, 2026 September 30, 2025 GAAP net income $ 19,292 $ 110,636 $ 1,675 Gain on sale of lab products business — (112,966) — Stock-based compensation expense 9,655 10,654 8,418 Business development and portfolio optimization expense* 5,527 11,078 — Acquisition related-amortization of purchased intangibles 3,894 529 1,602 Tax effect related to amortization of purchased intangibles — 54 (111) Impairment of intangible asset — — 2,258 Transformational initiative costs — — 524 Restructuring costs — — 530 Non-GAAP net income 38,368 19,985 14,896 Interest income (2,208) (1,735) (2,013) Income tax (income) expense (8,600) 3,828 96 Depreciation expense 3,308 2,286 2,213 Other (income) expense, net (372) 440 107 Adjusted EBITDA $ 30,496 $ 24,804 $ 15,299 * Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.
Page 13
CareDx, Inc. Reconciliation of Non-GAAP to Adjusted EBITDA (Unaudited) (In thousands) Year Ended December 31,2025 GAAP net loss $ (21,354) Stock-based compensation expense 34,864 Acquisition related-amortization of purchased intangibles 6,349 Acquisition related fees and expenses 204 Change in estimated fair value of contingent consideration 703 Tax effect related to amortization of purchased intangibles (431) Impairment of intangible asset 2,258 Transformational initiative costs 2,824 Restructuring costs 890 Litigation settlement expense 5,710 Non-GAAP net income 32,017 Interest income (9,174) Income tax expense 702 Depreciation expense 8,667 Other (income) expense, net (524) Adjusted EBITDA $ 31,688
Page 14
CareDx, Inc. Reconciliation of GAAP Net Income Margin to Adjusted EBITDA Margin (Unaudited) (In thousands, except percentages) Three Months Ended September 30, 2026 June 30, 2026 September 30, 2025 GAAP net income $ 19,292 $ 110,636 $ 1,675 GAAP net income margin 14 % 84 % 2 % Gain on sale of lab products business — (112,966) — Stock-based compensation expense 9,655 10,654 8,418 Business development and portfolio optimization expense* 5,527 11,078 — Acquisition related-amortization of purchased intangibles 3,894 529 1,602 Tax effect related to amortization of purchased intangibles — 54 (111) Impairment of intangible asset — — 2,258 Transformational initiative costs — — 524 Restructuring costs — — 530 Non-GAAP net income 38,368 19,985 14,896 Interest income (2,208) (1,735) (2,013) Income tax (income) expense (8,600) 3,828 96 Depreciation expense 3,308 2,286 2,213 Other (income) expense, net (372) 440 107 Adjusted EBITDA $ 30,496 $ 24,804 $ 15,299 Revenue $ 139,362 $ 131,948 $ 100,055 Adjusted EBITDA margin 22 % 19 % 15 % * Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.
Page 15
CareDx, Inc. Net Cash Provided by Operating Activities Reconciliation to Free Cash Flow (Unaudited) (In thousands) Three Months Ended September 30, 2026 2025 Net cash provided by operating activities (GAAP) $ 12,718 $ 37,358 Less: item not included in free cash flows Capital expenditures (GAAP) $ (1,615) $ (1,305) Free cash flow (non-GAAP) $ 11,103 $ 36,053